|
gptkbp:instanceOf
|
prodrug
antihypertensive drug
|
|
gptkbp:administeredBy
|
oral route
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2002
|
|
gptkbp:ATCCode
|
gptkb:C09CA08
|
|
gptkbp:bioavailability
|
26% (olmesartan)
|
|
gptkbp:CASNumber
|
gptkb:144689-63-4
|
|
gptkbp:chemicalFormula
|
imidazole derivative
|
|
gptkbp:contraindication
|
pregnancy
severe renal impairment
|
|
gptkbp:developedBy
|
gptkb:Daiichi_Sankyo
|
|
gptkbp:drugClass
|
gptkb:angiotensin_II_receptor_antagonist
|
|
gptkbp:eliminationHalfLife
|
10-15 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
20 mg
5 mg
40 mg
|
|
gptkbp:hasMolecularFormula
|
C29H30N6O6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
olmesartan medoxomil
|
|
gptkbp:interactsWith
|
gptkb:NSAIDs
lithium
potassium-sparing diuretics
|
|
gptkbp:KEGGID
|
D01214
|
|
gptkbp:lactationWarning
|
not recommended
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Benicar
gptkb:Olmetec
Olmesar
|
|
gptkbp:mechanismOfAction
|
angiotensin II receptor blocker
|
|
gptkbp:MedlinePlusID
|
a603006
|
|
gptkbp:MeSH_ID
|
gptkb:D000077321
|
|
gptkbp:metabolism
|
gptkb:olmesartan
|
|
gptkbp:patentExpired
|
2016 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause fetal toxicity
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
gptkb:DB00275
130881
|
|
gptkbp:RxNorm
|
310797
|
|
gptkbp:sideEffect
|
diarrhea
dizziness
headache
|
|
gptkbp:synonym
|
CS-866
RO-31-3896
|
|
gptkbp:UNII
|
7K5X768F5X
|
|
gptkbp:usedFor
|
treatment of hypertension
|
|
gptkbp:bfsParent
|
gptkb:Oltrumet
gptkb:olmesartan
|
|
gptkbp:bfsLayer
|
7
|